A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis

  • Hubbard R
  • McElvaney N
  • Birrer P
  • et al.
184Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

CYSTIC fibrosis is a lethal recessive genetic disorder caused by mutations of the cystic fibrosis transmembrane conductance regulator, a gene comprising 27 exons and 250 kilobases that resides on chromosome 7. 1 2 3 4 5 The most important clinical manifestation of cystic fibrosis is chronic progressive lung disease, which despite aggressive antibiotic therapy and chest physiotherapy, remains the principal cause of disability and death. 1 Airway secretions play a major part in the respiratory dysfunction in cystic fibrosis. The secretions are thick, viscous, and difficult to expectorate, and they obstruct airways and contribute to reduced lung volumes and expiratory flow rates. 1 , 2 , 6 The presence of high. © 1992, Massachusetts Medical Society. All rights reserved.

Cite

CITATION STYLE

APA

Hubbard, R. C., McElvaney, N. G., Birrer, P., Shak, S., Robinson, W. W., Jolley, C., … Crystal, R. G. (1992). A Preliminary Study of Aerosolized Recombinant Human Deoxyribonuclease I in the Treatment of Cystic Fibrosis. New England Journal of Medicine, 326(12), 812–815. https://doi.org/10.1056/nejm199203193261207

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free